Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study).

Matteo Brunelli,Sara Elena Rebuzzi,Valerio Gaetano Vellone,Marta Sbaraglia,Gabriele Gaggero,Matteo Fassan,Marco Maruzzo,Umberto Basso,Melissa Bersanelli,Alessandra Damassi,Valentino Martelli,Fabio Catalano,Francesco Pierantoni,Chiara Casartelli,Sara Merler,Gianluca Businello,Michele Milella,Sebastiano Buti,Giuseppe Fornarini

Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study).

2021

Matteo Brunelli
Sara Elena Rebuzzi
Valerio Gaetano Vellone
Marta Sbaraglia
Gabriele Gaggero
Matteo Fassan
Marco Maruzzo
Umberto Basso
Melissa Bersanelli
Alessandra Damassi
Valentino Martelli
Fabio Catalano
Francesco Pierantoni
Chiara Casartelli
Sara Merler
Gianluca Businello
Michele Milella
Sebastiano Buti
Giuseppe Fornarini

e16545Background: The Meet-URO 18 study is ongoing to assess the prognostic role of I-TME in advanced RCC patients treated with ≥second line nivolumab divided into two cohorts according to clinical...

Keywords:

Renal cell carcinoma
Immunotherapy
Immune system
Nivolumab
Oncology
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations